focus -WSS

focus

author：hotspot 2025-09-30 20:26:26 - browse：81

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The release of Novo Nordisk’s latest earnings report on Thursday provided a chance for executives to tout their major win this week — outcomes from a large trial showing the company’s obesity drug Wegovy cut the risk of heart complications by 20%.

But once again, much of the attention was focused on the company’s struggles to meet what Novo CEO Lars Fruergaard Jørgensen referred to as the “overwhelming demand for Wegovy.”

Jørgensen reiterated that the company was racing to expand supply and had brought on more contract manufacturing support, but Novo said Thursday that the company would continue to restrict the availability of lower-strength starter doses in the United States to ensure that patients on the drug would not have their medication interrupted.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： FDA panel to weigh safety of artificial wombs for preterm births

knowledge

hotspot

WSS

The struggle to figure out which patients 'deserve' Wegovy

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

FDA panel to weigh safety of artificial wombs for preterm births

Why Novartis is changing the name of its research labs

Eli Lilly CEO gives to Mike Pence presidential super PAC

A rare thyroid diagnosis led to unexpected, all

hotspot

focus

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

A new House health package & hospitals’ new site

Medical records are filled with copy

The struggle to figure out which patients 'deserve' Wegovy

Wildfire smoke exposes gaps in outdoor worker protections

How the messy conversation about Dolly changed bioethics

Malaria cases in Florida and Texas: Here’s what you need to know

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

New air purifier tech could be key to improving indoor air quality

Why the drug industry's warnings on the IRA's impact fall short

knowledge

Grad students accuse University of California of wage theft

Grad students accuse University of California of wage theft

FDA panel to weigh safety of artificial wombs for preterm births

FDA panel to weigh safety of artificial wombs for preterm births

FDA weighs limits of animal data in assessing artificial wombs

House panel takes first step toward fixing drug shortages

knowledge

focus

hotspot

explore